• Universitat de València (49%)
• Universitat Jaume I (51%)

• Victoria Gonçalves Pina 
• Marcileia Zanatta 

Chronic wounds, inflammatory skin disorders and tissue damage represent a major healthcare and economic burden. Current treatments include corticosteroids, recombinant growth factors, biomaterials and mesenchymal stem cell (MSC) therapies. However, these approaches present limitations such as systemic side effects, low stability, biological variability and regulatory challenges linked to live cell administration.

Extracellular vesicles (exosomes) derived from MSCs have shown strong regenerative and immunomodulatory effects, but current technologies lack standardization and scalability.

Therefore, there is a need for a safe, standardized and scalable regenerative solution that preserves MSC therapeutic benefits without the risks associated with live cell therapies.

Researchers at the Universitat de València and Universitat Jaume I have developed a novel composition and method based on extracellular vesicles derived from mesenchymal stem cells with enhanced regenerative and anti-inflammatory properties.

The invention includes:

• An optimized isolation and production method.
• A stabilized bioactive formulation.
• A therapeutic application in tissue and skin regeneration

The invention preserves the paracrine regenerative effects of MSCs while improving safety, reproducibility and industrial feasibility.

Applications:

• Regenerative medicine (chronic wounds, burns, tissue repair)
• Dermatology
• Pharmaceutical development

The main advantages of the invention are:

• Improved safety over live cell therapies
• Standardized and reproducible product
• Strong regenerative and immunomodulatory capacity
• Easier regulatory pathway

• Patent applied